

July 30, 2009

**For further information
please contact:**Dr Werner Lanthaler
Chief Executive Officer+49.(0)40.560 81-242
+49.(0)40.560 81-333 Fax
werner.lanthaler@evotec.comEvotec AG
Schnackenburgallee 114
22525 Hamburg
Germany
www.evotec.com**Evotec to Report First Half 2009 Results on August 7, 2009****Hamburg, Germany** – Evotec AG (Frankfurt Stock Exchange: EVT, NASDAQ: EVTC) will report its financial results for the first half of 2009 on Friday, August 7, 2009.

The Company is going to hold a conference call to discuss the results:

Conference call details:Date: Friday, August 7, 2009
Time: 09.30 a.m. CEST
08.30 a.m. BST
03.30 a.m. US time (East Coast)From Europe: +49.(0)69.5007 1308 (Germany)
+44.(0)20.7806 1956 (UK)From the US: +1.718.354 1388
Access Code: 8676443A simultaneous slide presentation for participants dialing in via phone is available at www.equitystory.com, password: evotec0809.**Webcast details**To join the *audio webcast* and to access the *presentation slides* you will find a link on our home page www.evotec.com shortly before the event.A replay of the conference call will be available for 24 hours and can be accessed in Europe by dialing +49.(0)69.22222 0418 (Germany) or +44.(0)20.7806 1970 (UK) and in the US by +1.718.354 1112. The access code is 8676443#. The on-demand version of the webcast will be available on our website: www.evotec.com - Investors – Financial Reports.**About Evotec AG**

Evotec is a leader in the discovery and development of novel small molecule drugs. The Company has built substantial drug discovery expertise and an industrialized platform that can drive new innovative small molecule compounds into the clinic. In addition, Evotec has built a deep internal knowledge base in the treatment of diseases related to neuroscience, pain, and inflammation. Leveraging these skills and expertise the Company intends to develop best-in-class differentiated therapeutics and deliver superior science-driven discovery alliances with pharmaceutical and biotechnology companies.

Evotec has long-term discovery alliances with partners including Boehringer Ingelheim, CHDI, Novartis, Ono Pharmaceutical and Roche. The Company has a P2X₇ antagonist for the treatment of inflammatory diseases in clinical development and a

series of preclinical compounds and development partnerships, including a strategic alliance with Roche for EVT 101, a subtype selective NMDA receptor antagonist, for use in treatment-resistant depression.